Multiple ways to kill bacteria via inhibiting novel cell wall or membrane targets.

Future Medicinal Chemistry
George A Naclerio, Herman O Sintim

Abstract

The rise of antibiotic-resistant infections has been well documented and the need for novel antibiotics cannot be overemphasized. US FDA approved antibiotics target only a small fraction of bacterial cell wall or membrane components, well-validated antimicrobial targets. In this review, we highlight small molecules that inhibit relatively unexplored cell wall and membrane targets. Some of these targets include teichoic acids-related proteins (DltA, LtaS, TarG and TarO), lipid II, Mur family enzymes, components of LPS assembly (MsbA, LptA, LptB and LptD), penicillin-binding protein 2a in methicillin-resistant Staphylococcus aureus, outer membrane protein transport (such as LepB and BamA) and lipoprotein transport components (LspA, LolC, LolD and LolE). Inhibitors of SecA, cell division protein, FtsZ and compounds that kill persister cells via membrane targeting are also covered.

References

Jun 1, 1991·Journal of Bacteriology·K Dai, J Lutkenhaus
Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·D B OliverG P Jarosik
Oct 1, 1965·Proceedings of the National Academy of Sciences of the United States of America·D J Tipper, J L Strominger
Dec 1, 1984·Antimicrobial Agents and Chemotherapy·S SommaA Corti
Apr 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·M TokunagaH C Wu
Feb 26, 1998·Cell·K E MatlackT A Rapoport
Jun 17, 1998·Nature Structural Biology·E NogalesJ Löwe
Dec 5, 1998·Microbiology and Molecular Biology Reviews : MMBR·C Goffin, J M Ghuysen
Feb 17, 2001·Infection and Immunity·I R Henderson, J P Nataro
Jun 5, 2002·Annual Review of Biochemistry·Christian R H Raetz, Chris Whitfield
Jan 31, 2003·Expert Opinion on Investigational Drugs·Neil Woodford
Dec 9, 2003·Nature·Bert Van den BergTom A Rapoport
Dec 11, 2003·Microbiology and Molecular Biology Reviews : MMBR·Francis C Neuhaus, James Baddiley
Jan 27, 2004·Journal of Molecular Evolution·Sue VaughanStephen G Addinall
Aug 12, 2004·The Journal of Biological Chemistry·William T DoerrlerChristian R H Raetz
Sep 29, 2004·FEMS Microbiology Letters·Naomi E KramerEefjan Breukink
Mar 15, 2006·Nature Reviews. Drug Discovery·Eefjan Breukink, Ben de Kruijff
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Samy O MerouehShahriar Mobashery
Oct 1, 1928·Journal of Bacteriology·L A Rogers, E O Whittier
May 10, 2006·Biochemistry·D N GanchevB de Kruijff
Jul 11, 2006·Molecular Microbiology·Juliana C MalinverniThomas J Silhavy
Aug 15, 2006·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·H Nikaido
May 8, 2007·Proceedings of the National Academy of Sciences of the United States of America·Angelika Gründling, Olaf Schneewind
Jul 31, 2007·Biochemical Pharmacology·Prerna DomadiaDebjani Dasgupta

❮ Previous
Next ❯

Citations

Jan 6, 2021·Medicine in Drug Discovery·Gregory UpertPhilipp Ermert
Mar 7, 2021·International Journal of Molecular Sciences·George A NaclerioHerman O Sintim
Dec 30, 2020·Chemical Reviews·Jed F Fisher, Shahriar Mobashery
Sep 23, 2020·Journal of Medicinal Chemistry·George A NaclerioHerman O Sintim

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03582007
NCT03409679

Related Concepts